Uncategorized
Acucela Provides Important Company Updates
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has made significant progress on the three strategic imperatives previously announced in its 2014 Annual Report to Shareholders to increase the value of the Company and enhance shareholder return: maximizing the value of emixu
